Lumiracoxib
(Redirected from Prexige)
An encyclopedia article about Lumiracoxib
Overview[edit | edit source]
Lumiracoxib is a nonsteroidal anti-inflammatory drug (NSAID) that belongs to the class of cyclooxygenase-2 (COX-2) inhibitors. It is used for the treatment of osteoarthritis and acute pain. Lumiracoxib is known for its selective inhibition of the COX-2 enzyme, which plays a role in the inflammatory process.
Mechanism of Action[edit | edit source]
Lumiracoxib works by selectively inhibiting the COX-2 enzyme, which is responsible for the synthesis of prostaglandins that mediate inflammation, pain, and fever. Unlike traditional NSAIDs, which inhibit both COX-1 and COX-2, lumiracoxib's selectivity for COX-2 reduces the risk of gastrointestinal side effects associated with COX-1 inhibition.
Pharmacokinetics[edit | edit source]
Lumiracoxib is rapidly absorbed after oral administration, with peak plasma concentrations occurring approximately 2 hours post-dose. It is extensively metabolized in the liver, primarily by the cytochrome P450 enzyme system, and is excreted mainly in the urine.
Clinical Use[edit | edit source]
Lumiracoxib is indicated for the relief of symptoms associated with osteoarthritis, such as pain and inflammation. It is also used for the management of acute pain in various conditions. However, its use is limited due to concerns about cardiovascular safety and liver toxicity.
Safety and Side Effects[edit | edit source]
Common side effects of lumiracoxib include gastrointestinal discomfort, headache, and dizziness. Serious side effects may include cardiovascular events such as myocardial infarction and stroke, as well as liver damage. Due to these risks, lumiracoxib has been withdrawn from the market in several countries.
Regulatory Status[edit | edit source]
Lumiracoxib was approved for use in several countries but has faced regulatory challenges due to safety concerns. It has been withdrawn from the market in many regions, including the European Union and Australia, due to reports of severe liver injury.
Related pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
